|
|
|
|
|
|
|
|
|
|
|
|
|
26.06.26 - 12:00
|
Ionis grants Recordati rights to zilganersen for Alexander disease (PBR)
|
|
|
Ionis will retain the responsibility for commercialising the RNA-targeted medicine within the US and will remain the global lead for development activities. Under the agreement, Recordati will handle regulatory
The post Ionis grants Recordati rights to zilganersen for Alexander disease appeared first on Pharmaceutical Business review....
|
|
|
|
|
25.06.26 - 12:39
|
Ionis Pharmaceuticals Aktie: Milliardenchance für Tryngolza? (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Ionis Pharmaceuticals-Aktienanalyse von Goldman Sachs:
Goldman Sachs habe das Kursziel für die Aktie von Ionis Pharmaceuticals Inc. (ISIN: US4622221004, WKN: A2ACMZ, Ticker-Symbol: ISI, NASDAQ-Symbol: IONS) leicht von 74 auf 75 USD angehoben und die Einstufung "neutral" bestätigt. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
08.06.26 - 13:03
|
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors (Business Wire)
|
|
|
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective immediately.“We are pleased to welcome Dr. Hantson to the board,” said Joseph Loscalzo, M.D., Ph.D., chairman of the Ionis Board of Directors. “Ludwig's biopharma executive leadership experience will be especially meaningful as Ionis prepares for a steady cadence of new commercial launches, including two additional independent launches this year, while continuing to scale its operations as a fully integrated biotechnology company.”Dr. Hantson has more than 30 years of leadership experience at biopharmaceutical and medical device companies. He served as chief executive officer and board member of Alexion from 2017-2021, prior to its acquisition by AstraZeneca. Under his leadership, Dr. Hantson redefined the company's strategy and operating model and strengthened execution ...
|
|
|
|
|
|
|
|
|
19.05.26 - 18:18
|
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk (24/7 Wall St.)
|
|
|
BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company's transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with Citi's simultaneous Buy initiation Buy ratings on peer biotechs Alnylam, Ascendis Pharma, BioMarin, Cytokinetics, and of Ionis Pharmaceuticals (NASDAQ:IONS), making the BBIO Neutral a cautious outlier. For ... Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn't a Slam Dunk...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
